메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
최지원 (연세대학교 의과대학 세브란스병원 약무국) 금민정 (연세대학교 세브란스병원 약무국) 고종희 (연세대학교 세브란스병원) 손은선 (연세대학교의료원 세브란스병원 약무국) 유윤미 (연세대학교)
저널정보
한국병원약사회 병원약사회지 병원약사회지 제40권 제2호
발행연도
2023.5
수록면
183 - 194 (12page)
DOI
https://doi.org/10.32429/jkshp.2023.40.2.003

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background : Graft-versus-host disease (GVHD) is a complication reported in 30–50% of patients who receive homologous hematopoietic stem cell transplantation. Although systemic corticosteroids are recommended as primary treatment, approximately 50% develop steroid-refractory GVHD (SR-GVHD) with high mortality. In May 2022, ruxolitinib was approved by the Ministry of Food and Drug Safety for the treatment of SR-GVHD, but there is limited data on treatment responses in Korean patients. The purpose of this study was to evaluate the effectiveness of ruxolitinib in patients with SR-GVHD. Methods : We enrolled patients with GVHD who had received ruxolitinib treatement at Severance Hospital between January 2017 to July 2022. We evaluated the overall response rate (ORR) and non-relapse mortality (NRM) at the time of ruxolitinib discontinuation. Patients and GVHD characteristics were analyzed according to the responder and non-responder groups of ruxolitinib, and the steroid-sparing effect was estimated based on whether the co-administered steroids were reduced. Results : There were no significant differences in baseline patient characteristics and GVHD characteristics between the responder and non-responder groups. The overall responsive rate (ORR) for ruxolitinib was 50% (22 of 44 patients). During the administration of ruxolitinib, 91% of responders and 46% of non-responders experienced a reduction of steroid dose reduction (p<0.01). The NRM was 10% in the responder group and 64% in the non-responder group (p<0.01), and the main cause of death was infection. Conclusion : The results demonstrate that ruxolitinib has a steroid-sparing effect in patients with SR-GVHD, as evidenced by the higher number of patients who experienced steroid dose reduction and the lower NRM in responders than non-responders. This suggests the possibility of reducing steroid-induced infection risk and mortality.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0